PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32979497-0	2020	Nitric oxide synthase inhibition with N(G)-monomethyl-L-arginine: determining the window of effect in the human vasculature.	omega-N-Methylarginine	38-64	nitric oxide synthase 2	Homo sapiens	0-21	
34377119-9	2021	L-NMMA can block the increase of iNOS and ncNOS protein expression and the ability to inhibit proliferation caused by isoproterenol.	omega-N-Methylarginine	0-6	nitric oxide synthase 2	Homo sapiens	33-37	
32979497-1	2020	Nitric oxide synthase (NOS) inhibition with N(G)-monomethyl-L-arginine (L-NMMA) is often used to assess the role of NO in human cardiovascular function.	omega-N-Methylarginine	44-70	nitric oxide synthase 2	Homo sapiens	0-21	
32979497-1	2020	Nitric oxide synthase (NOS) inhibition with N(G)-monomethyl-L-arginine (L-NMMA) is often used to assess the role of NO in human cardiovascular function.	omega-N-Methylarginine	72-78	nitric oxide synthase 2	Homo sapiens	0-21	
29912480-5	2018	The non-selective inhibitor of nitric oxide synthase (NOS) - N-methyl-l-arginine (LNMMA), the donor of NO - S-Nitroso-N-acetylpenicillamine (SNAP) or morphine (in the amount of 10-4 M) were used at the time of re-oxygenation.	omega-N-Methylarginine	82-87	nitric oxide synthase 2	Homo sapiens	31-52	
32439003-5	2020	Endothelial function was assessed by forearm blood flow (FBF) response to acetylcholine, and nitric oxide synthase (NOS) activity was defined as the inverse of FBF reserve to NG-monomethyl-L-arginine.	omega-N-Methylarginine	175-199	nitric oxide synthase 2	Homo sapiens	93-114	
32104540-3	2020	The viability of fungi treated with HaCaT cells alone and with HaCaT cells combined with pretreatment with the NADPH oxidase inhibitor (DPI) or the nitric oxide synthase (NOS) inhibitor L-NMMA was determined by enumerating the colony-forming units.	omega-N-Methylarginine	186-192	nitric oxide synthase 2	Homo sapiens	148-169	
31267172-13	2019	This effect was reversible by the addition of the iNOS inhibitor NG-monomethyl-L-arginine.	omega-N-Methylarginine	65-89	nitric oxide synthase 2	Homo sapiens	50-54	
30611984-1	2019	Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is a key enzyme involved in the metabolism of the endogenous nitric oxide synthase (NOS) inhibitors asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA).	omega-N-Methylarginine	210-216	nitric oxide synthase 2	Homo sapiens	111-132	
29301832-8	2018	To quantify proliferation and apoptosis, PDX tumor samples were stained using Ki67 and TUNEL assay.Results:In vitro, L-NMMA ameliorated the iNOS upregulation associated with docetaxel.	omega-N-Methylarginine	117-123	nitric oxide synthase 2	Homo sapiens	140-144	
25793525-1	2015	OBJECTIVE: We determined, for packed red blood cells (PRBC) and fresh frozen plasma, the maximum content, and ability to release the endogenous nitric oxide synthase (NOS) inhibitors asymmetric dimethylarginine (ADMA) and monomethylarginine (LNMMA).	omega-N-Methylarginine	242-247	nitric oxide synthase 2	Homo sapiens	144-165	
28013386-5	2017	We further hypothesized any effect of SDF on exercise hyperemia would be abolished with intra-arterial infusion of the NO synthase (NOS) inhibitor L-NG-monomethyl arginine (L-NMMA).	omega-N-Methylarginine	147-171	nitric oxide synthase 2	Homo sapiens	119-130	
28013386-5	2017	We further hypothesized any effect of SDF on exercise hyperemia would be abolished with intra-arterial infusion of the NO synthase (NOS) inhibitor L-NG-monomethyl arginine (L-NMMA).	omega-N-Methylarginine	173-179	nitric oxide synthase 2	Homo sapiens	119-130	
25593639-6	2015	In hypoxic condition, HRE-luciferase activity and VEGF expression were inhibited by the treatment with N(G)-monomethyl-L-arginine (L-NMMA), an inhibitor to nitric oxide synthase (NOS), which is accompanied with a decrease in Tbeta4 expression.	omega-N-Methylarginine	103-129	nitric oxide synthase 2	Homo sapiens	156-177	
25593639-6	2015	In hypoxic condition, HRE-luciferase activity and VEGF expression were inhibited by the treatment with N(G)-monomethyl-L-arginine (L-NMMA), an inhibitor to nitric oxide synthase (NOS), which is accompanied with a decrease in Tbeta4 expression.	omega-N-Methylarginine	131-137	nitric oxide synthase 2	Homo sapiens	156-177	
22925810-7	2013	The combined stimulation also enhanced iNOS mRNA expression and the NO production was abrogated by an iNOS inhibitor, NG-monomethyl L-arginine.	omega-N-Methylarginine	118-142	nitric oxide synthase 2	Homo sapiens	39-43	
24130344-5	2013	Functional NO activity in the renal circulation was determined as change of RPF to infusion of the NO synthase (NOS) inhibitor N(G)-monomethyl-L-arginine (L-NMMA) (4.25 mg/kg).	omega-N-Methylarginine	127-153	nitric oxide synthase 2	Homo sapiens	99-110	
24130344-5	2013	Functional NO activity in the renal circulation was determined as change of RPF to infusion of the NO synthase (NOS) inhibitor N(G)-monomethyl-L-arginine (L-NMMA) (4.25 mg/kg).	omega-N-Methylarginine	155-161	nitric oxide synthase 2	Homo sapiens	99-110	
23395999-8	2013	The iNOS inhibitor N(G)-monomethyl-l-arginine (l-NMMA) reduced both cytokine-induced phagocytosis and phagocytosis induced by the combination of cytokines plus DCF.	omega-N-Methylarginine	19-45	nitric oxide synthase 2	Homo sapiens	4-8	
23395999-8	2013	The iNOS inhibitor N(G)-monomethyl-l-arginine (l-NMMA) reduced both cytokine-induced phagocytosis and phagocytosis induced by the combination of cytokines plus DCF.	omega-N-Methylarginine	47-53	nitric oxide synthase 2	Homo sapiens	4-8	
23582621-1	2013	OBJECTIVES: Monomethylated L-arginine (L-NMMA) has been proven to be a strong inhibitor of nitric oxide synthase (NOS) and has been used as an exogenous tool in experimental evaluation of cerebrovascular reactivity leading to vasoconstriction.	omega-N-Methylarginine	39-45	nitric oxide synthase 2	Homo sapiens	91-112	
23773265-4	2013	The measurements were performed at rest and during exercise without (control) and with blockade of nitric oxide synthase (NOS) with NG-monomethyl-l-arginine (L-NMMA).	omega-N-Methylarginine	132-156	nitric oxide synthase 2	Homo sapiens	99-120	
23773265-4	2013	The measurements were performed at rest and during exercise without (control) and with blockade of nitric oxide synthase (NOS) with NG-monomethyl-l-arginine (L-NMMA).	omega-N-Methylarginine	158-164	nitric oxide synthase 2	Homo sapiens	99-120	
22925810-7	2013	The combined stimulation also enhanced iNOS mRNA expression and the NO production was abrogated by an iNOS inhibitor, NG-monomethyl L-arginine.	omega-N-Methylarginine	118-142	nitric oxide synthase 2	Homo sapiens	102-106	
21664477-9	2011	Incubation of the explants with the nitric oxide synthase (NOS) inhibitor L-NMMA (100 muM) caused a significant decrease in CBF relative to baseline (p < 0.01) which developed over 20 min and remained stable thereafter.	omega-N-Methylarginine	74-80	nitric oxide synthase 2	Homo sapiens	36-57	
22484031-5	2012	The magnitude of the increase in central augmentation index (cAIx) in response to inhibition of NO synthase (NOS) by l-NMMA is indicative of basal NO activity.	omega-N-Methylarginine	117-123	nitric oxide synthase 2	Homo sapiens	96-107	
22081702-4	2012	Molecular patch-clamp studies confirmed that nanomolar concentrations of TES stimulated BK(Ca) channel activity by ~100-fold and that inhibition of nitric oxide synthase (NOS) activity by N(G)-monomethyl-L-arginine nearly abolished this effect.	omega-N-Methylarginine	188-214	nitric oxide synthase 2	Homo sapiens	148-169	
18808317-1	2008	Tilarginine is L-N-monomethyl arginine (L-NMMA) or N(G)-monomethyl-L-arginine HCL, a non-selective inhibitor of nitric oxide synthase (NOS), which has been studied in the treatment of septic shock and cardiogenic shock complicating myocardial infarction.	omega-N-Methylarginine	0-11	nitric oxide synthase 2	Homo sapiens	112-133	
20817701-1	2010	Intracoronary infusions of acetylcholine (ACh) and the nitric oxide synthase (NOS) inhibitor N(G)-monomethyl-l-arginine (l-NMMA) are routinely used to assess endothelial function in the human coronary circulation.	omega-N-Methylarginine	93-119	nitric oxide synthase 2	Homo sapiens	55-76	
20817701-1	2010	Intracoronary infusions of acetylcholine (ACh) and the nitric oxide synthase (NOS) inhibitor N(G)-monomethyl-l-arginine (l-NMMA) are routinely used to assess endothelial function in the human coronary circulation.	omega-N-Methylarginine	121-127	nitric oxide synthase 2	Homo sapiens	55-76	
19292882-1	2009	BACKGROUND: The haemodynamic effects of intravenous infusion of the non-selective nitric oxide synthase (NOS) L-omega monomethyl arginine (L-NMMA) have previously been characterized in humans.	omega-N-Methylarginine	139-145	nitric oxide synthase 2	Homo sapiens	82-103	
19081984-4	2009	The complexes bearing guanidino substituted analogues of l-arginine still present considerable inhibitory action (N(omega)-monomethyl-l-arginine, K(i) = 36 microM; N(omega)-nitro-l-arginine, K(i) = 84 microM), being the first examples of organometallic complexes able to inhibit the iNOS.	omega-N-Methylarginine	113-144	nitric oxide synthase 2	Homo sapiens	283-287	
20216951-2	2010	These AGEs are structurally analogous to endogenous inhibitors of nitric oxide synthases (NOS) including N(G)-monomethyl-L-arginine (L-NMMA) and asymmetric N(G),N(G)-dimethyl-L-arginine (ADMA).	omega-N-Methylarginine	105-131	nitric oxide synthase 2	Homo sapiens	66-88	
17892399-8	2007	NO release and cytotoxic activity are inhibited by N-monomethyl-L-arginine (L-NMMA), a specific inhibitor of the NO pathway and increased by L-arginine, an NO precursor, and tetrahydrobiopterin (BH4), a nitric oxide synthase (NOS) cofactor.	omega-N-Methylarginine	51-74	nitric oxide synthase 2	Homo sapiens	203-224	
17941092-6	2007	The inhibitory effects of SNP and iNOS on TGF-beta1 expression were reduced in cells treated with NO scavengers N-dithiocarboxysarcosine (DTCS), 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO), and hemoglobin, or with the iNOS inhibitor N-methyl-arginine (NMA).	omega-N-Methylarginine	251-268	nitric oxide synthase 2	Homo sapiens	34-38	
17941092-6	2007	The inhibitory effects of SNP and iNOS on TGF-beta1 expression were reduced in cells treated with NO scavengers N-dithiocarboxysarcosine (DTCS), 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO), and hemoglobin, or with the iNOS inhibitor N-methyl-arginine (NMA).	omega-N-Methylarginine	270-273	nitric oxide synthase 2	Homo sapiens	34-38	
17660388-1	2007	We studied the impact of systemic infusion of the nitric oxide synthase (NOS) inhibitor N(G)-monomethyl-L-arginine (L-NMMA) on coronary flow reserve (CFR) in patients with coronary artery disease (CAD).	omega-N-Methylarginine	88-114	nitric oxide synthase 2	Homo sapiens	50-71	
17660388-1	2007	We studied the impact of systemic infusion of the nitric oxide synthase (NOS) inhibitor N(G)-monomethyl-L-arginine (L-NMMA) on coronary flow reserve (CFR) in patients with coronary artery disease (CAD).	omega-N-Methylarginine	116-122	nitric oxide synthase 2	Homo sapiens	50-71	
17724209-3	2007	In the present study, the authors hypothesized that either the alpha-receptor agonist phenylephrine or the nitric oxide synthase (NOS) inhibitor L-NMMA may alter the choroidal blood flow response during a transition from light to dark.	omega-N-Methylarginine	145-151	nitric oxide synthase 2	Homo sapiens	107-128	
17339088-5	2007	The NO synthase (NOS) inhibitor N(G)-monomethyl-L-arginine (1 mM) reduced basal levels of c-GMP by 50% but had no effect on telomerase activity or replicative capacity.	omega-N-Methylarginine	32-58	nitric oxide synthase 2	Homo sapiens	4-15	
17892399-8	2007	NO release and cytotoxic activity are inhibited by N-monomethyl-L-arginine (L-NMMA), a specific inhibitor of the NO pathway and increased by L-arginine, an NO precursor, and tetrahydrobiopterin (BH4), a nitric oxide synthase (NOS) cofactor.	omega-N-Methylarginine	76-82	nitric oxide synthase 2	Homo sapiens	203-224	
17273169-1	2007	Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA) are endogenously produced amino acids that inhibit all three isoforms of nitric oxide synthase (NOS).	omega-N-Methylarginine	60-66	nitric oxide synthase 2	Homo sapiens	141-162	
17211666-2	2007	Tadpoles exposed to S-nitro-N-acetylpenicillamine (SNAP), an NO-donor, or L: -arginine, the substrate of NO synthase (NOS), showed a reversible decrease, whereas animals exposed to the NOS inhibitor Nomega-methyl-L: -arginine (L: -NMMA) exhibited an increase in ammonium release.	omega-N-Methylarginine	199-225	nitric oxide synthase 2	Homo sapiens	105-116	
17211666-2	2007	Tadpoles exposed to S-nitro-N-acetylpenicillamine (SNAP), an NO-donor, or L: -arginine, the substrate of NO synthase (NOS), showed a reversible decrease, whereas animals exposed to the NOS inhibitor Nomega-methyl-L: -arginine (L: -NMMA) exhibited an increase in ammonium release.	omega-N-Methylarginine	227-235	nitric oxide synthase 2	Homo sapiens	105-116	
16698551-1	2006	Dimethylarginine dimethylaminohydrolase (DDAH) is involved in the regulation of nitric oxide synthase (NOS) by metabolizing the free endogenous arginine derivatives N(omega)-methyl-L-arginine (MMA) and N(omega),N(omega)-dimethyl-L-arginine (ADMA), which are competitive inhibitors of NOS.	omega-N-Methylarginine	165-191	nitric oxide synthase 2	Homo sapiens	80-101	
16927020-7	2006	Experiments using an inhibitor of iNOS, N-monomethyl-L-arginine (NMA), together with nicotine confirmed the involvement of NO in the drug action, abrogating completely cell death and a good part of the genotoxicity.	omega-N-Methylarginine	65-68	nitric oxide synthase 2	Homo sapiens	34-38	
16787198-10	2006	L-arginine inhibits platelet aggregation both in vitro and in vivo, while L-NMMA (NG-monomethyl-L-arginine), an endogenous L-arginine analogue and inhibitor of NO synthase (NOS), increases platelet activation and adhesion.	omega-N-Methylarginine	82-106	nitric oxide synthase 2	Homo sapiens	160-171	
16360110-5	2006	In comparison with l-NAME and AG, l-NMMA strongly inhibited iNOS activity.	omega-N-Methylarginine	34-40	nitric oxide synthase 2	Homo sapiens	60-64	
16585199-5	2006	Activation of NO synthase (NOS) activity was crucial for sanguinarine-induced cell death because NOS inhibitor L-NMMA efficiently protected cells from apoptosis.	omega-N-Methylarginine	111-117	nitric oxide synthase 2	Homo sapiens	14-25	
16620268-4	2006	We sought to investigate the effect of diabetes on basal cerebrovascular endothelial function as assessed by response to the nitric oxide synthase (NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA).	omega-N-Methylarginine	163-187	nitric oxide synthase 2	Homo sapiens	125-146	
16360110-6	2006	By using this method, the K(m) value of Arg and the K(i) value of l-NMMA for iNOS were determined to be 12.6 and 6.1muM, respectively.	omega-N-Methylarginine	66-72	nitric oxide synthase 2	Homo sapiens	77-81	
16864162-4	2006	Retinal capillary flow was assessed with scanning laser Doppler flowmetry at rest and following systemic infusion of the nitric oxide synthase (NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA).	omega-N-Methylarginine	159-183	nitric oxide synthase 2	Homo sapiens	121-142	
16435353-10	2006	The NOS inhibitor, L-NMMA, inhibited the effects of iNOS on the cells.	omega-N-Methylarginine	19-25	nitric oxide synthase 2	Homo sapiens	52-56	
16332518-7	2006	Application of L-NG monomethyl arginine (L-NMMA), an NO synthase (NOS) inhibitor, reduced the production of NO at the basal level.	omega-N-Methylarginine	15-39	nitric oxide synthase 2	Homo sapiens	53-64	
16332518-7	2006	Application of L-NG monomethyl arginine (L-NMMA), an NO synthase (NOS) inhibitor, reduced the production of NO at the basal level.	omega-N-Methylarginine	41-47	nitric oxide synthase 2	Homo sapiens	53-64	
16306196-2	2005	We hypothesized that combination therapy with an NO synthase (NOS) inhibitor [N(G)-monomethyl-L-arginine (L-NMMA)] and indomethacin would produce tighter ductus constriction than indomethacin alone.	omega-N-Methylarginine	78-104	nitric oxide synthase 2	Homo sapiens	49-60	
16306196-2	2005	We hypothesized that combination therapy with an NO synthase (NOS) inhibitor [N(G)-monomethyl-L-arginine (L-NMMA)] and indomethacin would produce tighter ductus constriction than indomethacin alone.	omega-N-Methylarginine	106-112	nitric oxide synthase 2	Homo sapiens	49-60	
15895825-4	2005	Pre-treatment with L-mono-methyl-arginine and N-acetyl-cysteine in oxidized low-density lipoprotein (ox-LDL) exposed HA cells, inhibited not only nitrite but also superoxide production suggesting that O2(-) anion could partially derive from inducible NO synthase.	omega-N-Methylarginine	19-41	nitric oxide synthase 2	Homo sapiens	241-262	
15839849-2	2005	The aim of this study was to estimate the effect of Nitric Oxide synthase (NOS)-inhibition (L-NMMA) on the diameter of the middle cerebral artery (MCA) and on regional cerebral blood flow (rCBF).	omega-N-Methylarginine	92-98	nitric oxide synthase 2	Homo sapiens	52-73	
15716663-10	2005	The ROS production could be inhibited by L-NMMA co-incubation, indicating that iNOS is responsible for the up-regulation (P<0.05).	omega-N-Methylarginine	41-47	nitric oxide synthase 2	Homo sapiens	79-83	
15561702-8	2005	Overexpression of inducible NO synthase increased the formation of S-nitroso-HCy, which was inhibited by the NO synthase inhibitor N-monomethyl-l-arginine.	omega-N-Methylarginine	131-154	nitric oxide synthase 2	Homo sapiens	18-39	
12810424-8	2003	L-NMMA decreased basal flow significantly more (-34+/-2%) in the patients with RA than the normal subjects (-24+/-3%, p<0.02), suggesting in view of the blunted response to ACh, increased iNOS activity.	omega-N-Methylarginine	0-6	nitric oxide synthase 2	Homo sapiens	191-195	
15554917-3	2004	The l-arginine analogues asymmetric dimethylarginine (ADMA) and N(G)-monomethyl-l-arginine (l-NMMA) are endogenous inhibitors of nitric oxide synthase (NOS), involved in the physiopathology of arterial hypertension.	omega-N-Methylarginine	64-90	nitric oxide synthase 2	Homo sapiens	129-150	
15289288-6	2004	Albumin-induced expression of iNOS protein was inhibited by cycloheximide and NO production was abolished after incubation of the cells with an iNOS inhibitor, N(G)-monomethyl-l-arginine (LNMMA).	omega-N-Methylarginine	160-186	nitric oxide synthase 2	Homo sapiens	30-34	
15289288-6	2004	Albumin-induced expression of iNOS protein was inhibited by cycloheximide and NO production was abolished after incubation of the cells with an iNOS inhibitor, N(G)-monomethyl-l-arginine (LNMMA).	omega-N-Methylarginine	160-186	nitric oxide synthase 2	Homo sapiens	144-148	
15289288-6	2004	Albumin-induced expression of iNOS protein was inhibited by cycloheximide and NO production was abolished after incubation of the cells with an iNOS inhibitor, N(G)-monomethyl-l-arginine (LNMMA).	omega-N-Methylarginine	188-193	nitric oxide synthase 2	Homo sapiens	30-34	
15289288-6	2004	Albumin-induced expression of iNOS protein was inhibited by cycloheximide and NO production was abolished after incubation of the cells with an iNOS inhibitor, N(G)-monomethyl-l-arginine (LNMMA).	omega-N-Methylarginine	188-193	nitric oxide synthase 2	Homo sapiens	144-148	
15342423-9	2004	Myeloid suppressor cell-induced immunosuppression is mediated by nitric oxide production via inducible nitric oxide synthase (iNOS) because the specific iNOS inhibitor, l-NMMA, restored antigen-specific T-cell responsiveness in vitro.	omega-N-Methylarginine	169-175	nitric oxide synthase 2	Homo sapiens	93-124	
15342423-9	2004	Myeloid suppressor cell-induced immunosuppression is mediated by nitric oxide production via inducible nitric oxide synthase (iNOS) because the specific iNOS inhibitor, l-NMMA, restored antigen-specific T-cell responsiveness in vitro.	omega-N-Methylarginine	169-175	nitric oxide synthase 2	Homo sapiens	126-130	
15342423-9	2004	Myeloid suppressor cell-induced immunosuppression is mediated by nitric oxide production via inducible nitric oxide synthase (iNOS) because the specific iNOS inhibitor, l-NMMA, restored antigen-specific T-cell responsiveness in vitro.	omega-N-Methylarginine	169-175	nitric oxide synthase 2	Homo sapiens	153-157	
13680036-2	2003	NG monomethyl L-arginine ( L-NMMA:546C88) is an inhibitor of all three NO synthases (NOS), the enzymes that catalyse the production of NO.	omega-N-Methylarginine	0-24	nitric oxide synthase 2	Homo sapiens	71-83	
13680036-2	2003	NG monomethyl L-arginine ( L-NMMA:546C88) is an inhibitor of all three NO synthases (NOS), the enzymes that catalyse the production of NO.	omega-N-Methylarginine	27-33	nitric oxide synthase 2	Homo sapiens	71-83	
12810424-10	2003	Basal blood flow is increased in proportion to inflammatory activity and more inhibited by L-NMMA, suggesting increased iNOS activity, and responsiveness to NO is reduced.	omega-N-Methylarginine	91-97	nitric oxide synthase 2	Homo sapiens	120-124	
10936516-8	2000	The antimycobacterial effect in macrophages was reversed by the iNOS inhibitor N-monomethyl L-arginine (NMMA), suggesting that CRL-1072 promotes killing of MAI by inducing NO.	omega-N-Methylarginine	79-102	nitric oxide synthase 2	Homo sapiens	64-68	
12419308-9	2002	Treatment with N(G)-monomethyl-L-arginine, a competitive inhibitor of inducible nitric oxide synthase (iNOS), was able to protect ceramide-dependent CYP3A4 suppression.	omega-N-Methylarginine	15-41	nitric oxide synthase 2	Homo sapiens	70-101	
12419308-9	2002	Treatment with N(G)-monomethyl-L-arginine, a competitive inhibitor of inducible nitric oxide synthase (iNOS), was able to protect ceramide-dependent CYP3A4 suppression.	omega-N-Methylarginine	15-41	nitric oxide synthase 2	Homo sapiens	103-107	
11862754-2	2002	Free intracellular L-NMMA and ADMA, but not SDMA, are inhibitors of all three isoforms of nitric oxide synthases (nNOS, eNOS and iNOS).	omega-N-Methylarginine	19-25	nitric oxide synthase 2	Homo sapiens	129-133	
11063913-8	2000	Both nonselective (N(G)-monomethyl-L-arginine) and specific (N-Iminoethyl-L-lysine) inhibitors of iNOS significantly increased leukocyte binding by normal HIMEC activated with cytokines and lipopolysaccharide (LPS), but had no effect on leukocyte adhesion by similarly activated IBD HIMEC.	omega-N-Methylarginine	19-45	nitric oxide synthase 2	Homo sapiens	98-102	
12560087-11	2003	Importantly, endogenous formation of NO in RCC4 cells via inducible NO synthase elicited S-nitrosation of HIF-1 alpha that was sensitive to inhibition of inducible NO synthase activity with N-monomethyl-L-arginine.	omega-N-Methylarginine	190-213	nitric oxide synthase 2	Homo sapiens	58-79	
12560087-11	2003	Importantly, endogenous formation of NO in RCC4 cells via inducible NO synthase elicited S-nitrosation of HIF-1 alpha that was sensitive to inhibition of inducible NO synthase activity with N-monomethyl-L-arginine.	omega-N-Methylarginine	190-213	nitric oxide synthase 2	Homo sapiens	154-175	
11833101-6	2002	The effect of Chinese herbal medicine on the peritoneal lymphatic stomata and the drainage of urinary ion was altered by adding NO donor(sodium nitropurruside,SNP) or NO synthase (NOS) inhibitor (N(G)-monomethyl-L-arginine, L-NMMA) to the peritoneal cavity.	omega-N-Methylarginine	196-222	nitric oxide synthase 2	Homo sapiens	167-178	
11134047-5	2001	The protective effects of S1P were reversed by the nitric-oxide synthase (NOS) inhibitor N-monomethyl-l-arginine, but not by the soluble guanylyl cyclase inhibitor 1H-(1,2,4)oxadiazolo[4,3-a]-quanoxaline-1-one, suggesting that NO, but not cGMP, is responsible for S1P protection from apoptosis.	omega-N-Methylarginine	89-112	nitric oxide synthase 2	Homo sapiens	51-72	
10960730-4	2000	Nitric oxide formation and cell death were significantly decreased by N(G)-monomethyl-L-arginine (L-NMMA), a nitric oxide-synthase (NOS; EC 1.14.13.39) inhibitor.	omega-N-Methylarginine	70-96	nitric oxide synthase 2	Homo sapiens	109-130	
10960730-4	2000	Nitric oxide formation and cell death were significantly decreased by N(G)-monomethyl-L-arginine (L-NMMA), a nitric oxide-synthase (NOS; EC 1.14.13.39) inhibitor.	omega-N-Methylarginine	98-104	nitric oxide synthase 2	Homo sapiens	109-130	
10936516-8	2000	The antimycobacterial effect in macrophages was reversed by the iNOS inhibitor N-monomethyl L-arginine (NMMA), suggesting that CRL-1072 promotes killing of MAI by inducing NO.	omega-N-Methylarginine	104-108	nitric oxide synthase 2	Homo sapiens	64-68	
10799301-3	2000	Inhibition of LPS/IFN-gamma-induced NO synthesis with the L-arginine analogue N(G)-monomethyl-L-arginine (L-NMMA) was accompanied by a significant up-regulation of iNOS mRNA that was reversed in the presence of the NO donor sodium nitroprusside (SNP).	omega-N-Methylarginine	78-104	nitric oxide synthase 2	Homo sapiens	164-168	
10677552-4	2000	An inhibitor of NO synthase (NOS), N(G)-monomethyl-l-arginine (NMMA), prevented the increase in medium concentrations of AA and LH-RH induced by high [K(+)], suggesting that NO mediates release of both AA and LH-RH.	omega-N-Methylarginine	35-61	nitric oxide synthase 2	Homo sapiens	16-27	
10751195-2	2000	These cells contain the inducible isoform of nitric oxide (NO) synthase (iNOS), and insulin-stimulated cGMP production in confluent cultured cells is blocked by the NOS inhibitor, N(G)-monomethyl-L-arginine (L-NMMA).	omega-N-Methylarginine	180-206	nitric oxide synthase 2	Homo sapiens	73-77	
10751195-2	2000	These cells contain the inducible isoform of nitric oxide (NO) synthase (iNOS), and insulin-stimulated cGMP production in confluent cultured cells is blocked by the NOS inhibitor, N(G)-monomethyl-L-arginine (L-NMMA).	omega-N-Methylarginine	208-214	nitric oxide synthase 2	Homo sapiens	73-77	
10677552-4	2000	An inhibitor of NO synthase (NOS), N(G)-monomethyl-l-arginine (NMMA), prevented the increase in medium concentrations of AA and LH-RH induced by high [K(+)], suggesting that NO mediates release of both AA and LH-RH.	omega-N-Methylarginine	63-67	nitric oxide synthase 2	Homo sapiens	16-27	
10329044-10	1999	Blocking iNOS activity by NG-monomethyl-l-arginine (l-NMA) significantly reduced the sensitization, Fas mRNA, and protein expression observed with IFN-gamma pretreatment of the tumor cells.	omega-N-Methylarginine	26-50	nitric oxide synthase 2	Homo sapiens	9-13	
10803407-9	2000	Inhibition of NO synthesis by N(G)-monomethyl-L-arginine produced marked dose-dependent attenuation of PAF-mediated NO release, indicating nitric oxide synthase (NOS) activation.	omega-N-Methylarginine	30-56	nitric oxide synthase 2	Homo sapiens	139-160	
10690326-1	1999	The guanidino-methylated arginine analogue NG monomethyl-L-arginine (L-NMMA) has been the standard nitric oxide synthase inhibitor used to evaluate the role of the L-arginine:nitric oxide pathway.	omega-N-Methylarginine	69-75	nitric oxide synthase 2	Homo sapiens	99-120	
10362675-2	1999	At rest, NO synthase (NOS) inhibition by intra-arterial infusion of NG-monomethyl-L-arginine decreased femoral artery blood flow (FABF, ultrasound Doppler) from 0.39 +/- 0.08 to 0.18 +/- 0.03 l/min (P < 0.	omega-N-Methylarginine	68-92	nitric oxide synthase 2	Homo sapiens	9-20	
9824439-7	1998	The L-Arg-mediated NK cell activation was abolished by addition of NG-monomethyl-L-arginine, an inhibitor for iNOS.	omega-N-Methylarginine	67-91	nitric oxide synthase 2	Homo sapiens	110-114	
10067972-3	1999	An inhibitor of nitric oxide synthase (NOS), NG-monomethyl-L-arginine (L-NMMA; 50 micromoles/kg body weight infused simultaneously with VEGF), was used to explore the role of nitric oxide in mediating the vascular changes induced by VEGF.	omega-N-Methylarginine	45-69	nitric oxide synthase 2	Homo sapiens	16-37	
10374875-8	1999	In NOS inhibitor (NG-monomethyl-L-arginine: L-NMMA)-containing medium, an iNOS-positive ATL cell line (K3T) showed growth inhibition and DNA ladder.	omega-N-Methylarginine	18-42	nitric oxide synthase 2	Homo sapiens	74-78	
10374875-8	1999	In NOS inhibitor (NG-monomethyl-L-arginine: L-NMMA)-containing medium, an iNOS-positive ATL cell line (K3T) showed growth inhibition and DNA ladder.	omega-N-Methylarginine	44-50	nitric oxide synthase 2	Homo sapiens	74-78	
9743513-3	1998	METHODS AND RESULTS: VSMCs transiently transfected with iNOS cDNA functionally expressed 130 kd iNOS protein with full catalytic activity to generate massive NO in proportion to the doses of cDNA used; its enzymatic activity as well as NO production was completely blocked by an NOS inhibitor, NG-monomethyl-L-arginine (LNMMA).	omega-N-Methylarginine	294-318	nitric oxide synthase 2	Homo sapiens	56-60	
9743513-3	1998	METHODS AND RESULTS: VSMCs transiently transfected with iNOS cDNA functionally expressed 130 kd iNOS protein with full catalytic activity to generate massive NO in proportion to the doses of cDNA used; its enzymatic activity as well as NO production was completely blocked by an NOS inhibitor, NG-monomethyl-L-arginine (LNMMA).	omega-N-Methylarginine	294-318	nitric oxide synthase 2	Homo sapiens	96-100	
9743513-3	1998	METHODS AND RESULTS: VSMCs transiently transfected with iNOS cDNA functionally expressed 130 kd iNOS protein with full catalytic activity to generate massive NO in proportion to the doses of cDNA used; its enzymatic activity as well as NO production was completely blocked by an NOS inhibitor, NG-monomethyl-L-arginine (LNMMA).	omega-N-Methylarginine	320-325	nitric oxide synthase 2	Homo sapiens	56-60	
9743513-3	1998	METHODS AND RESULTS: VSMCs transiently transfected with iNOS cDNA functionally expressed 130 kd iNOS protein with full catalytic activity to generate massive NO in proportion to the doses of cDNA used; its enzymatic activity as well as NO production was completely blocked by an NOS inhibitor, NG-monomethyl-L-arginine (LNMMA).	omega-N-Methylarginine	320-325	nitric oxide synthase 2	Homo sapiens	96-100	
9207456-5	1997	NO production was blocked by N(G)-monomethyl-L-arginine (NMMA), an inhibitor of NO synthase (NOS), and by the antioxidant N-acetylcysteine (NAC).	omega-N-Methylarginine	29-55	nitric oxide synthase 2	Homo sapiens	80-91	
9724273-4	1998	Both nonselective (NG-monomethyl-L-arginine) and specific (N-iminoethyl-L-lysine) competitive inhibitors of iNOS significantly increased binding of leukocytes by HIMEC activated with cytokines and lipopolysaccharide.	omega-N-Methylarginine	19-43	nitric oxide synthase 2	Homo sapiens	108-112	
9623681-10	1998	Nitrite production was inhibited by N(G)-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of iNOS.	omega-N-Methylarginine	36-62	nitric oxide synthase 2	Homo sapiens	100-104	
9623681-10	1998	Nitrite production was inhibited by N(G)-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of iNOS.	omega-N-Methylarginine	64-70	nitric oxide synthase 2	Homo sapiens	100-104	
9401778-6	1997	A role for NO as a mediator of N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced chemotaxis was supported by the finding that the NO synthase (NOS) inhibitor L-NMMA (500 microM) inhibited chemotaxis; EC50 for fMLP 28.76 +/- 5.62 and 41.13 +/- 4.77 pmol/10(6) cells with and without L-NMMA, respectively.	omega-N-Methylarginine	163-169	nitric oxide synthase 2	Homo sapiens	135-146	
9401778-6	1997	A role for NO as a mediator of N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced chemotaxis was supported by the finding that the NO synthase (NOS) inhibitor L-NMMA (500 microM) inhibited chemotaxis; EC50 for fMLP 28.76 +/- 5.62 and 41.13 +/- 4.77 pmol/10(6) cells with and without L-NMMA, respectively.	omega-N-Methylarginine	287-293	nitric oxide synthase 2	Homo sapiens	135-146	
9596680-9	1998	Furthermore, the inhibition of endogenous NO production with the inducible NO synthase inhibitor NG-monomethyl-L-arginine caused a complete abrogation of the apoptotic effect.	omega-N-Methylarginine	97-121	nitric oxide synthase 2	Homo sapiens	65-86	
9585809-4	1998	L-NMMA and aminoguanidine, competitive inhibitors of iNOS suppressed NO production as measured by the NO byproduct, nitrite, as did IFN-B.	omega-N-Methylarginine	0-6	nitric oxide synthase 2	Homo sapiens	53-57	
9645394-3	1998	The inhibitors of the iNOS pathway, aminoguanidine and NG-monomethyl-L-arginine (L-NMMA), suppressed the production of .NO and enhanced the steady-state concentration of O2.- determined.	omega-N-Methylarginine	55-79	nitric oxide synthase 2	Homo sapiens	22-26	
9645394-3	1998	The inhibitors of the iNOS pathway, aminoguanidine and NG-monomethyl-L-arginine (L-NMMA), suppressed the production of .NO and enhanced the steady-state concentration of O2.- determined.	omega-N-Methylarginine	81-87	nitric oxide synthase 2	Homo sapiens	22-26	
9307076-8	1997	Nitrite production was enhanced when the MDM were primed (pretreated) with gamma or alpha interferon or other immune mediators such as IL-4 and was reduced by the iNOS inhibitor, N-methyl-L-arginine (L-NMMA).	omega-N-Methylarginine	200-206	nitric oxide synthase 2	Homo sapiens	163-167	
9207456-5	1997	NO production was blocked by N(G)-monomethyl-L-arginine (NMMA), an inhibitor of NO synthase (NOS), and by the antioxidant N-acetylcysteine (NAC).	omega-N-Methylarginine	57-61	nitric oxide synthase 2	Homo sapiens	80-91	
9151791-4	1997	Blood flow and albumin permeation were increased approximately 2.5-fold 1 h after topical application of recombinant human VEGF and these effects were prevented by nitric oxide synthase (NOS) inhibitors (aminoguanidine and N(G)-monomethyl L-arginine).	omega-N-Methylarginine	223-249	nitric oxide synthase 2	Homo sapiens	164-185	
9202399-3	1997	NO synthase (NOS) inhibitors with affinity for the inducible (iNOS) and the constitutive (cNOS) isoform such as N(G)-monomethyl-L-arginine (L-NMMA) and S-methyl-L-thiocitrulline (SMLT) dose-dependently blocked the inhibitory action of IFN-gamma on GHRH-stimulated GH secretion, and partially reversed the inhibitory effect on basal prolactin (PRL) release.	omega-N-Methylarginine	112-138	nitric oxide synthase 2	Homo sapiens	0-11	
9202399-3	1997	NO synthase (NOS) inhibitors with affinity for the inducible (iNOS) and the constitutive (cNOS) isoform such as N(G)-monomethyl-L-arginine (L-NMMA) and S-methyl-L-thiocitrulline (SMLT) dose-dependently blocked the inhibitory action of IFN-gamma on GHRH-stimulated GH secretion, and partially reversed the inhibitory effect on basal prolactin (PRL) release.	omega-N-Methylarginine	140-146	nitric oxide synthase 2	Homo sapiens	0-11	
9160832-5	1997	Pretreatment of these cells with N(G)-monomethyl-L-arginine (L-NMMA; 1 mM), an inhibitor of iNOS, prevented the sepiapterin-mediated induction of .NO and restored gene transfer to baseline values.	omega-N-Methylarginine	33-59	nitric oxide synthase 2	Homo sapiens	92-96	
9160832-5	1997	Pretreatment of these cells with N(G)-monomethyl-L-arginine (L-NMMA; 1 mM), an inhibitor of iNOS, prevented the sepiapterin-mediated induction of .NO and restored gene transfer to baseline values.	omega-N-Methylarginine	61-67	nitric oxide synthase 2	Homo sapiens	92-96	
9237255-6	1997	An NO synthase (NOS) inhibitor, NG-monomethyl-L-arginine (LNMMA), significantly stimulated the basal oestradiol release and dose-dependently enhanced the oestradiol and progesterone release from follicle stimulating hormone (FSH)-stimulated PGC in a 24 h culture.	omega-N-Methylarginine	32-56	nitric oxide synthase 2	Homo sapiens	3-14	
9237255-6	1997	An NO synthase (NOS) inhibitor, NG-monomethyl-L-arginine (LNMMA), significantly stimulated the basal oestradiol release and dose-dependently enhanced the oestradiol and progesterone release from follicle stimulating hormone (FSH)-stimulated PGC in a 24 h culture.	omega-N-Methylarginine	58-63	nitric oxide synthase 2	Homo sapiens	3-14	
8928785-3	1996	iNOS activity and NO synthesis were inhibited by nitro-L-arginine methyl ester, NG-monomethyl-L-arginine, S-methyl-isothiourea sulfate, or aminoethyl-isothiourea, but not by dexamethasone.	omega-N-Methylarginine	80-104	nitric oxide synthase 2	Homo sapiens	0-4	
21533398-3	1997	It was found that the co-culture of BEC with human TNF-alpha caused an increase of NO synthesis which could be completely blocked by the treatment with inducible NO synthase (iNOS) inhibitor N-G-monomethyl-L-arginine (NMMA).	omega-N-Methylarginine	191-216	nitric oxide synthase 2	Homo sapiens	152-173	
21533398-3	1997	It was found that the co-culture of BEC with human TNF-alpha caused an increase of NO synthesis which could be completely blocked by the treatment with inducible NO synthase (iNOS) inhibitor N-G-monomethyl-L-arginine (NMMA).	omega-N-Methylarginine	191-216	nitric oxide synthase 2	Homo sapiens	175-179	
21533398-3	1997	It was found that the co-culture of BEC with human TNF-alpha caused an increase of NO synthesis which could be completely blocked by the treatment with inducible NO synthase (iNOS) inhibitor N-G-monomethyl-L-arginine (NMMA).	omega-N-Methylarginine	218-222	nitric oxide synthase 2	Homo sapiens	152-173	
21533398-3	1997	It was found that the co-culture of BEC with human TNF-alpha caused an increase of NO synthesis which could be completely blocked by the treatment with inducible NO synthase (iNOS) inhibitor N-G-monomethyl-L-arginine (NMMA).	omega-N-Methylarginine	218-222	nitric oxide synthase 2	Homo sapiens	175-179	
8896420-5	1996	Inhibition of iNOS activity by NG-monomethyl-L-arginine (LNMMA) significantly decreased in vitro U937 cell differentiation with VD and RA/VD as shown by the expression of cell differentiation markers (CD14 and CD68) and by the capacity of these cells to undergo a luminol-dependent chemiluminescence in response to opsonized zymosan.	omega-N-Methylarginine	57-62	nitric oxide synthase 2	Homo sapiens	14-18	
8764178-1	1996	We tested the ability of NG-monomethyl-L-arginine (L-NMMA), an inhibitor of NO synthase (NOS), to suppress the osteogenic response in a recently developed model of mechanically induced osteogenesis.	omega-N-Methylarginine	25-49	nitric oxide synthase 2	Homo sapiens	76-87	
8764178-1	1996	We tested the ability of NG-monomethyl-L-arginine (L-NMMA), an inhibitor of NO synthase (NOS), to suppress the osteogenic response in a recently developed model of mechanically induced osteogenesis.	omega-N-Methylarginine	51-57	nitric oxide synthase 2	Homo sapiens	76-87	
8896420-5	1996	Inhibition of iNOS activity by NG-monomethyl-L-arginine (LNMMA) significantly decreased in vitro U937 cell differentiation with VD and RA/VD as shown by the expression of cell differentiation markers (CD14 and CD68) and by the capacity of these cells to undergo a luminol-dependent chemiluminescence in response to opsonized zymosan.	omega-N-Methylarginine	31-55	nitric oxide synthase 2	Homo sapiens	14-18	
7542684-6	1995	The NO synthase (NOS) inhibitors NG-monomethyl-L-arginine or nitro-L-arginine methyl ester did not affect methemoglobin generation from oxyhemoglobin induced by SNAP but inhibited that mediated by activated PMN with IC50 values of 250 microM and 340 microM, respectively.	omega-N-Methylarginine	33-57	nitric oxide synthase 2	Homo sapiens	4-15	
8748661-4	1995	5-HT-induced cGMP production was completely abolished by BAPTA, an intracellular Ca2+ chelating agent, or NG-mono-methyl-L-arginine(NMMA), a nitric oxide synthase (NOS) inhibitor, suggesting that 5-HT-induced cGMP generation was through nitric oxide (NO)-dependent pathway.	omega-N-Methylarginine	106-131	nitric oxide synthase 2	Homo sapiens	141-162	
7519434-6	1994	NO stimulated cGMP production in iNOS-transfected cells, and this effect was inhibited by the iNOS inhibitor NG-monomethyl-L-arginine.	omega-N-Methylarginine	109-133	nitric oxide synthase 2	Homo sapiens	33-37	
7519434-6	1994	NO stimulated cGMP production in iNOS-transfected cells, and this effect was inhibited by the iNOS inhibitor NG-monomethyl-L-arginine.	omega-N-Methylarginine	109-133	nitric oxide synthase 2	Homo sapiens	94-98	
7544846-4	1995	Nitric oxide is synthesized from a L-arginine by the cytoplasmic enzyme nitric oxide synthase (NOS) which is a calcium dependent enzyme, and this pathway is inhibited by the analogues of L-arginine such as NG-monomethyl-L-arginine (L-NMMA) and is augmented by NMDA receptor activation.	omega-N-Methylarginine	206-230	nitric oxide synthase 2	Homo sapiens	72-93	
7544846-4	1995	Nitric oxide is synthesized from a L-arginine by the cytoplasmic enzyme nitric oxide synthase (NOS) which is a calcium dependent enzyme, and this pathway is inhibited by the analogues of L-arginine such as NG-monomethyl-L-arginine (L-NMMA) and is augmented by NMDA receptor activation.	omega-N-Methylarginine	232-238	nitric oxide synthase 2	Homo sapiens	72-93